These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San Diego, California.
Shattuck Labs Reports Preclinical Data Demonstrating Therapeutic Utility Of TRIM7 Inhibition To Prevent Or Reverse Acquired Resistance To Immune Checkpoint Therapy
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.